A Novel Cocktail Drug Penetrates Heart Muscle and May Treat Nearly Half of All Patients with DMD
Duchenne muscular dystrophy (DMD) is a devastating disease that causes the body's muscle tissues to progressively waste away until all mobility is lost. Eventually, the heart muscle becomes fatty and fibrotic, typically leading to heart failure and death by age 30. There is no ...
Trainee Spotlight Series: Jakob Jung and Sara Overby
Date: April 21, 2022 Time: 11-12 EST, 5-6 CET Description: In our first of many Trainee Spotlights, we feature Jakob Jung and Sarah Overby. Jakob Jung is a Ph.D. candidate at the Institute for Molecular Infection Biology (IMIB), at the University of Würzburg. ...
Interview with Hermona Soreq, PhD
Hermona Soreq, PhDThe Slesinger Professor of Molecular Neuroscience at The Hebrew University of Jerusalem’s Edmond and Lily Safra Center for Brain Sciences (ELSC) and the Silberman Institute of Life Sciences How did you become interested in the field of oligonucleotides? During my PhD studies ...
Could a Single Oligonucleotide Medication Treat Multiple Different Diseases?
Our relatively new field is swiftly growing, and another exciting novel therapeutic RNA modality is now gaining traction. tRNA is vital in protein synthesis and by engineering tRNA molecules...
Chemical and Nanotechnology-based Approaches to Build Next-gen Oligonucleotide Therapeutics
Join Aurélie Lacroix, PhD and Leonora Abdullahu, PhD, the 2021/2022 OTS Trainee Reps, as they share about their research and career paths. Speaker: Aurélie Lacroix, PhD, Senior Scientist / MSCA fellow, Sixfold Bioscience Bio ...
Support for Ukrainian Scientists
The OTS joins other scientific organizations in seeking to help Ukrainian scientists. Specifically, we invite Ukrainian students, scientists, and industry professionals with interests in the field of nucleic acids and oligonucleotide therapeutics to post their contact information and CVs on the OTS website. We ...
Antisense Oligonucleotide-based Therapies for Inherited Retinal Diseases: From Mutation to Clinical Trial
Speaker: Alex Garanto, PhD Date: March 10, 2022 Time: 11-12 EST Description: The eye is at the forefront of therapeutic development for its unique properties. Local delivery of ASOs to the retina has shown to be well tolerated and safe. During this webinar, Prof. ...
A New ASO Shows Promise in Treating Dravet Syndrome, a Severe Form of Epilepsy
Typically, a single copy of a gene is enough to support normal growth and development but in a small subset of genes, the loss of one copy can cause serious diseases that are often difficult to treat. One of these conditions, Dravet Syndrome, has no ...
Meet Your 2022 OTS Trainee Reps
Speaker: Chantal Ferguson, MD, PhD Candidate and Hassan Fakih, PhD Date: February 24, 2022 Time: 11-12 EST Description: The OTS values and encourages the contribution of trainees to the society. The trainee representative to the Board of Directors position was created to give trainees ...
A Potent ASO Shows Encouraging Results in A Single-Patient Pilot Study for ALS
Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease in which motor neurons die. Since the motor neurons that die control voluntary muscles, the disease causes great difficulty for those who must live with it. They will experience loss of motor control of the arms ...
